Novo Growth – 2021, A Year in Review

• 11 new investments and four follow-on direct investments

• Expanded portfolio to 21 highly innovative, scalable long-term life science companies

• Portfolio value growth of c.US$360 million

• Total portfolio value of US$1.2 billion

Copenhagen, Denmark, 21 April 2022 – Novo Growth, the growth-stage investment arm of Novo Holdings, today publishes its annual newsletter.

Commenting on a highly successful year, Robert Ghenchev, Managing Partner, Head of Novo Growth, said: “Novo Growth’s unique platform combines deep life sciences expertise with long-term capital to make significant growth equity investments in companies across the life sciences industry.

We’re proud of the landmark accomplishments of our portfolio companies in the past year from bringing the first AI designed immuno-oncology drug into the clinic to the large-scale production of COVID-19 vaccines. We’re also excited about the potential of our new investments which use real-world data insights to bring new drugs to market, help patients receive life-saving dialysis in the home, and develop sustainable chemicals and materials to support a greener planet. We look forward to supporting the continued growth of companies that will impact the future of health and society.”

Founded in 2019 and based in San Francisco, Novo Growth has made 21 investments across the diversity of our focus areas, eleven of which are based in the US, seven based in Europe, and three in the Asia Pacific region. Two companies within our portfolio are publicly traded, including Exscientia, which had its IPO on Nasdaq in October 2021, while the remainder are private. Additionally, Novo Growth has taken select limited partnership positions with external fund managers to act as accelerators of our core direct investment strategy. These positions, together with our direct investments, comprise our portfolio value of US$1.2 billion (DKK 7.9 billion) as of the end of 2021.